Evaro appoints leading men’s health expert Prof. Geoffrey Hackett to address UK’s testosterone crisis

Sexual medicine specialist joins health tech pioneer to launch at-home testing service to tackle underdiagnosed condition affecting 40% of men over 45

NORWICH, UK – 26th June, 2025 – Digital health platform Evaro today announces the appointment of Professor Geoffrey Hackett, one of the UK's most distinguished experts in testosterone deficiency and men's sexual health, as the company expands its clinical capabilities to tackle a health crisis affecting millions of undiagnosed British men.

The appointment comes as 40% of men over 45 and 25% of men over 30 suffer from testosterone deficiency – a condition linked to increased mortality risk, cardiovascular disease, and significantly reduced quality of life. Despite affecting an estimated 2 million UK men, the condition remains critically underdiagnosed and undertreated.

Professor Hackett, former consultant urologist at University Hospitals Birmingham Foundation Trust and current Professor of Sexual Medicine at Aston University, brings wide-ranging expertise to Evaro's mission of making healthcare as accessible as online banking. Author of 180 original research papers and lead author of the definitive British Society for Sexual Medicine Guidelines on Testosterone Deficiency, he has already begun designing Evaro's comprehensive testosterone replacement therapy protocols that will be implemented across Evaro's B2C brands, e-Surgery and e-Pharmacy, as well as all partner brands.

Under Professor Hackett's guidance, Evaro is launching a comprehensive at-home testosterone testing and treatment service, eliminating traditional healthcare barriers that have left millions of men undiagnosed. The service combines AI-driven consultations with a nationwide phlebotomy network, allowing patients to receive comprehensive and accurate blood tests in their own homes – a game-changing approach for a condition that requires precise monitoring.

"We have millions of men suffering cardiovascular disease, diabetes complications and premature death because testosterone deficiency remains invisible in our healthcare system," said Professor Hackett. "Evaro's technology makes life-saving treatment possible for men who would otherwise never be diagnosed. When you can prevent heart attacks by treating hormone deficiency at home, it's a transformative medical innovation - and I couldn't be more excited to help make it a reality."

Dr Oskar Wenbar, COO and co-founder of Evaro, said: "Our goal is to attract the very best specialists to ensure that we are providing the most effective care for our patients, and that we’re filling important gaps in healthcare access.This appointment is a crucial part of that mission. Testosterone levels have plummeted 20% in two decades, yet over 95% of affected men remain undiagnosed. Professor Hackett's appointment means we can finally close this treatment gap by combining his extensive expertise and our technology to make diagnosis as simple as every other digital experience - at scale.”

The service addresses critical failings in current healthcare delivery, where men face weeks-long GP waiting times for initial consultations, followed by further delays for blood tests and specialist referrals. Professor Hackett's protocols enable Evaro to diagnose and initiate treatment through a seamless digital pathway while maintaining the highest clinical standards.  Professor Hackett is already training Evaro's clinical team and developing AI-enhanced decision-making tools that will enable the platform to collect and analyse patient data to optimise treatment outcomes continually.

The appointment follows Evaro's partnership with Lovehoney announced in May 2025, which made the sexual wellness brand the first major UK retailer to embed NHS healthcare services directly into its platform, including free access to contraception. With over 750,000 patients already served through Evaro's platform, the company has proven its embeddable healthcare infrastructure can deliver high quality, fast medical care at scale while maintaining the highest clinical standards.

About Professor Geoffrey Hackett 

Professor Hackett is a world-leading authority on testosterone deficiency and men's sexual health. He served as consultant urologist at University Hospitals Birmingham Foundation Trust for 26 years and has been Professor of Sexual Medicine at Aston University since 2017. Winner of the prestigious Zorgniotti-Newman Prize for his groundbreaking research on testosterone deficiency in diabetes, he has authored definitive treatment guidelines used across the UK and Europe.

About Evaro 

Evaro is an NHS-licensed digital health platform making healthcare as accessible as online banking. Founded by medical professionals Dr Thuria Wenbar and Dr Oskar Wenbar, the company serves over 750,000 patients through AI-driven consultations and prescription services. Evaro's portfolio includes the B2C brands e-Surgery and e-Pharmacy, alongside its embeddable healthcare infrastructure for partner brands. Evaro holds Care Quality Commission, General Pharmaceutical Council, and NHS licenses, positioning it uniquely to deliver both private and NHS-integrated healthcare services.